Presentation on theme: "Session 4 - Communities of practice Natural Products Drug Discovery The ICBG Program: A view from afar* Special thanks to Joshua Rosenthal of the NIH Fogarty."— Presentation transcript:
1 Session 4 - Communities of practice Natural Products Drug Discovery The ICBG Program: A view from afar*Special thanks to Joshua Rosenthal of the NIH Fogarty Center for his helpful discussions and figures on the ICBG program
2 Program goals and accomplishments ObjectivesInternational Cooperative Biodiversity GroupsBiodiversity explorationScientific and economic developmentBiodiversity conservationModeled on CBD ABS and Merck/InBIO agreementPIC, IP, and benefit sharingTransitional periodNew awards Philipines, Indonesiacontinuing Panama, Madagascar“ending” Uzbekastan/Kurdistan, Papua New Guinea, VietNam LaosFiji, Costa Rica (only two will survive)Down to six in the end800k/yrImplementationCompetitive research grants (NIH/NSF/USDA)Five years, $300 – 600k/year direct costsGroups required academic institution and/or NFP, partner country, industrial partnerThe grand challengeManaging expectationsTechnology vs. sociology
3 State of the field Commercial Competing technologies and strategies Combinatorial chemistryHTP and UHTP screeningTherapeutic targets/privileged stucturesEconomic pressuresDecline in new chemical entitiesBiodiversity as a commodityTransitional periodNew awards Philipines, Indonesiacontinuing Panama, Madagascar“ending” Uzbekastan/Kurdistan, Papua New Guinea, VietNam LaosFiji, Costa Rica (only two will survive)Down to six in the end800k/yrPoliticalUncertainty of accessUncertainty of provenanceUncertainty of benefit
7 Outcomes Drug discovery Other benefits 14 years $50 M (US govt)12 groups7 companies21 countries12,000 species1500 bioactive compounds0 drugs>12,000+ spp collected>1300 bioactive compounds isolated>4000 people trained (350 long term)Institutional capacity built in 16 countriesInformed bioprospecting policies in at least 6 countriesInitiated/ strengthened biodiversity reserves in 7 countriesTested models of intellectual property rights and benefit-sharing/Established 14 Trust Funds>500 publications
8 Market sizeApprox. $100BFrom A. Kuo and G.M.Garrity 2002 Exploiting Microbial Diversity,In Biodiversity of Microbial Life, J.T. Staley and A-L Reysenbach, ed,John Wiley
9 Why me? 1996 - present Professor, Microbiology & Molecular Genetics Cofounder - Genomic Standards Consortium, Editor-in-Chief of SIGS (current), Bergey’s Manual ( )Chair, International Committee on Systematics of ProkaryotesCofounder, NamesforLife, LLCMerck and Co., Microbial Resources GroupBioprospecting and culture acquisition agreements, culture collectionNatural products dereplicationCo-inventor on 22 natural product patents
Your consent to our cookies if you continue to use this website.